Specifications:
|
Tests |
Specifications |
Results |
|
Appearance |
White or off-white crystaline powder |
White |
|
Solubility |
Soluble in Chloroform; |
Conform |
|
ldentification |
(1)Maximum absorption in wavelength of 240 nm |
Conform |
|
(2)Infrared spectrum should be in accordance the dominant peak of contrast |
In accordance with the dominant peak of contrast |
|
|
Melting points |
182ºC-184ºC |
182ºC |
|
Related substances |
≤0.5% |
0.3% |
|
Single impurity |
≤0.3% |
0.2% |
|
Loss on drying |
≤1.0% |
0.8% |
|
[Assay]C17H11N5 |
≥98.0% |
99.2% |
|
Conclusion |
Conforms Specifications of Enterprise Standard. |
|
Detail:
Femara is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women.
Femara is intended for use only by women who are no longer of childbearing age. Possible candidates must have already ceased to menstruate. It is often used in patients who have already undergone other cancer treatments, such as radiation, chemotherapy, and used other cancer drugs, like tamoxifen. This nonsteroidal aromatase inhibitor may help prevent any remaining cancer cells from spreading.
Femara is used for the treatment of post-menopause breast cancer.
Femara is a powerful Aromatase Inhibitor that was developed to fight breast cancer. For athletes and bodybuilders, it is a drug used to combat the estrogenic side effects of anabolic steroids water-retention, acne and gynocomastia. It will also raise testosterone levels because of the lowered estrogen in the body.